290 related articles for article (PubMed ID: 24070327)
21. Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.
Ozkan T; Hekmatshoar Y; Pamuk H; Ozcan M; Yaman G; Yagiz GC; Akdemir C; Sunguroglu A
Mol Biol Rep; 2021 Feb; 48(2):1625-1631. PubMed ID: 33515349
[TBL] [Abstract][Full Text] [Related]
22. Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis.
Alves R; Gonçalves AC; Jorge J; Marques G; Ribeiro AB; Tenreiro R; Coucelo M; Diamond J; Oliveiros B; Pereira A; Freitas-Tavares P; Almeida AM; Sarmento-Ribeiro AB
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077209
[TBL] [Abstract][Full Text] [Related]
23. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
Neviani P; Harb JG; Oaks JJ; Santhanam R; Walker CJ; Ellis JJ; Ferenchak G; Dorrance AM; Paisie CA; Eiring AM; Ma Y; Mao HC; Zhang B; Wunderlich M; May PC; Sun C; Saddoughi SA; Bielawski J; Blum W; Klisovic RB; Solt JA; Byrd JC; Volinia S; Cortes J; Huettner CS; Koschmieder S; Holyoake TL; Devine S; Caligiuri MA; Croce CM; Garzon R; Ogretmen B; Arlinghaus RB; Chen CS; Bittman R; Hokland P; Roy DC; Milojkovic D; Apperley J; Goldman JM; Reid A; Mulloy JC; Bhatia R; Marcucci G; Perrotti D
J Clin Invest; 2013 Oct; 123(10):4144-57. PubMed ID: 23999433
[TBL] [Abstract][Full Text] [Related]
24. OCT1 and imatinib transport in CML: is it clinically relevant?
Watkins DB; Hughes TP; White DL
Leukemia; 2015 Oct; 29(10):1960-9. PubMed ID: 26122430
[TBL] [Abstract][Full Text] [Related]
25. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.
Baran Y; Ural AU; Gunduz U
Hematology; 2007 Dec; 12(6):497-503. PubMed ID: 17852433
[TBL] [Abstract][Full Text] [Related]
27. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
28. 7-Ketocholesterol overcomes drug resistance in chronic myeloid leukemia cell lines beyond MDR1 mechanism.
Rosa Fernandes L; Stern AC; Cavaglieri RC; Nogueira FC; Domont G; Palmisano G; Bydlowski SP
J Proteomics; 2017 Jan; 151():12-23. PubMed ID: 27343758
[TBL] [Abstract][Full Text] [Related]
29. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
[TBL] [Abstract][Full Text] [Related]
30. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
[TBL] [Abstract][Full Text] [Related]
31. GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.
Han SH; Korm S; Han YG; Choi SY; Kim SH; Chung HJ; Park K; Kim JY; Myung K; Lee JY; Kim H; Kim DW
Autophagy; 2019 Dec; 15(12):2076-2090. PubMed ID: 30929559
[TBL] [Abstract][Full Text] [Related]
32. Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile.
Vasconcelos FC; Gattass CR; Rumjanek VM; Maia RC
Invest New Drugs; 2007 Dec; 25(6):525-33. PubMed ID: 17520174
[TBL] [Abstract][Full Text] [Related]
33. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
Losson H; Gajulapalli SR; Lernoux M; Lee JY; Mazumder A; Gérard D; Seidel C; Hahn H; Christov C; Dicato M; Kirsch G; Han BW; Schnekenburger M; Diederich M
Pharmacol Res; 2020 Oct; 160():105058. PubMed ID: 32619722
[TBL] [Abstract][Full Text] [Related]
34. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
[TBL] [Abstract][Full Text] [Related]
35. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.
Peng XX; Tiwari AK; Wu HC; Chen ZS
Chin J Cancer; 2012 Feb; 31(2):110-8. PubMed ID: 22098951
[TBL] [Abstract][Full Text] [Related]
37. KIF23 promotes autophagy-induced imatinib resistance in chronic myeloid leukaemia through activating Wnt/β-catenin pathway.
Huang Y; Yuan C; Liu Q; Wang L
Clin Exp Pharmacol Physiol; 2022 Dec; 49(12):1334-1341. PubMed ID: 36066385
[TBL] [Abstract][Full Text] [Related]
38. Drug transporters play a key role in the complex process of Imatinib resistance in vitro.
Alves R; Fonseca AR; Gonçalves AC; Ferreira-Teixeira M; Lima J; Abrantes AM; Alves V; Rodrigues-Santos P; Jorge L; Matoso E; Carreira IM; Botelho MF; Sarmento-Ribeiro AB
Leuk Res; 2015 Mar; 39(3):355-60. PubMed ID: 25575688
[TBL] [Abstract][Full Text] [Related]
39. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
[TBL] [Abstract][Full Text] [Related]
40. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
